Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eye drug shows promise for Diabetes-Related vision loss

NCT ID NCT05301751

First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 37 times

Summary

This study tested an experimental drug called AG-73305 in 25 adults with diabetic macular edema, a condition that causes vision loss due to diabetes. Participants received a single injection into the eye, and researchers monitored safety and vision changes over 6 months. The goal was to find the best dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Center of Macula and Retina Disease

    Winter Haven, Florida, 33880, United States

  • Retina Research Institute of Texas

    Abilene, Texas, 79606, United States

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida, 33711, United States

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas, 76087, United States

  • Texas Retina Associates

    Fort Worth, Texas, 76104, United States

  • Valley Retina Institute

    McAllen, Texas, 78503, United States

Conditions

Explore the condition pages connected to this study.